Arno Therapeutics To Present Three New Studies Supporting The Clinical Development Of Onapristone At American Association for Cancer Research Annual Meeting 2014
Published: Mar 26, 2014
FLEMINGTON, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new data from three research programs which support its investigational lead compound onapristone to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2014, being held April 5-9 in San Diego, California.
Help employers find you! Check out all the jobs and post your resume.